Evolving mEGFR 2+ L therapy

Back to meeting Original

Back to meeting

Jose Fernando Moura, PhD· @FernandoOnco · X·2026-10-26 17:06· 5 hours agoScore70

izalontamab

Body

Evolving mEGFR 2+ L therapy
Two trials, two differents ADCs 🇨🇳

Izalontamab-brengitecan bi-specific (HER3xEGFR), DAR 8
Ruzaltatug-rezetecan (HER3), DAR 4

Strong signals in PFS
@myESMO #ESMO26

25 views · 1 like · 0 reposts · 0 replies

Conference abstracts

2575PNCT06838273 NCT06838273 NCT06838273matched by NSCLC, locally advanced

Phase II study of izalontamab brengitecan (Iza-bren) plus osimertinib in patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer (NSCLC)

https://esmocongress.esmo.org

LBA50matched by Proffered paper 1: Breast cancer, early and advanced stage

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

Source: Jose Fernando Moura, PhD · x.com